Send the following on WhatsApp
Continue to ChatRegeneron、Sanofi 旗下 Libtayo,獲日本核准用於晚期或復發型子宮頸癌 https://geneonline.news/regeneron-sanofi-libtayo/?variant=zh-cn
Regeneron、Sanofi 旗下 Libtayo,獲日本核准用於晚期或復發型子宮頸癌 https://geneonline.news/regeneron-sanofi-libtayo/?variant=zh-cn